ASH 2025: Myelofibrosis Roundup

Recent advancements in myelofibrosis treatment signal a shift from traditional JAK inhibitors, with therapies like pelabresib showing positive results in combination with ruxolitinib. The 96-week data from the MANIFEST-2 trial highlights improved spleen volume reduction and comparable safety profiles compared to ruxolitinib alone. Concurrently, elritercept demonstrates robust efficacy in treating anemia within this patient population. Real-world studies affirm the long-term effectiveness of ruxolitinib, while stem cell transplants remain crucial for higher-risk patients, promising improved survival outcomes.